Ionis Prescribed drugs CEO Brett Monia sells $1.09 million in inventory

CARLSBAD, Calif. — Brett Monia, Chief Govt Officer of Ionis Prescribed drugs Inc. (NASDAQ:IONS), just lately bought a good portion of his holdings within the firm. In accordance with a current SEC submitting, Monia bought 33,445 shares of Ionis frequent inventory on January 16, 2025, at a median worth of $32.634 per share, producing proceeds of roughly $1.09 million. The transaction comes as Ionis shares commerce close to their 52-week low of $31.40, with the inventory down about 38% over the previous yr. In accordance with InvestingPro information, analysts keep a bullish outlook with worth targets starting from $37 to $78.

The transaction was a part of an automated sale to cowl tax withholding obligations associated to the vesting of restricted inventory models. Following this sale, Monia’s direct possession of Ionis inventory totals 207,396 shares.

Along with the sale, Monia acquired 73,448 shares of frequent inventory on January 15, 2025, via the vesting of restricted inventory models, though this transaction didn’t contain any money trade. This acquisition was half of a bigger transaction involving efficiency restricted inventory models and restricted inventory models granted underneath the corporate’s fairness incentive plan.

In different current information, Ionis Prescribed drugs has maintained its optimistic rankings from Piper Sandler and Needham following the FDA’s approval of its drug, TRYNGOLZA, for the therapy of Familial Chylomicronemia Syndrome (FCS). The newly authorised drug, which is Ionis Prescribed drugs’ first solo industrial drug launch, is priced at $595,000 per yr, aligning with the anticipated value for therapies focusing on ultra-rare illnesses. The corporate’s fast technique is to transition sufferers to the industrial drug within the first half of 2025. Piper Sandler tasks $37 million in U.S. FCS income for the fiscal yr 2025, whereas Needham’s income forecast for TRYNGOLZA in the identical yr stands at $27 million. These are current developments within the firm’s journey, because it additionally reported its third-quarter monetary outcomes for 2024, emphasizing non-GAAP financials. Ionis Prescribed drugs is poised for a brand new section of economic drug distribution, with analyst corporations reminiscent of Needham and TD Cowen expressing confidence within the firm’s market place and the potential of TRYNGOLZA.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.